Adalimumab (D2E7), a fully human anti-TNF-a monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy

Category Primary study
JournalArthritis Rheum
Year 2002
This article has no abstract
Epistemonikos ID: b30a01a5ee7a1a5a60e47dc5c19273ea2e369a77
First added on: Oct 25, 2017